Dr. Jerald H. Simmons, MD
Sleep Medicine (Sleep Medicine (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 751
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Ohio State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Sleep Medicine (Psychiatry & Neurology) Physician primary
TX license K7614 (first issued 1999; active) -
Clinical Neurophysiology Physician
TX license K7614 (first issued 1999; active) -
Neurology Physician
TX license K7614 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Comprehensive Sleep Medicine Associates, PA (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 751
- Services billed
- 3,712
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 2,040 | 570 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 403 | 52 |
| Established patient office or other outpatient visit, 40-54 minutes | 222 | 147 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 173 | 86 |
| Therapy procedure using a positive pressure ventilator | 129 | 116 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 108 | 108 |
| Study of esophagus to assess movement | 98 | 87 |
| Sleep study in sleep lab (6 years or older) | 87 | 85 |
| Established patient office or other outpatient visit, 30-39 minutes | 81 | 65 |
| New patient office or other outpatient visit, 60-74 minutes | 81 | 81 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methylphenidate Hcl Other prescribers in Houston, TX | 21 |
| Methadone Hcl Other prescribers in Houston, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 51 payments worth $1,552 in total to this clinician.
| Inspire Medical Systems, Inc. | $474 |
|---|---|
| Avadel Cns Pharmaceuticals, LLC | $443 |
| Jazz Pharmaceuticals Inc. | $352 |
| Harmony Biosciences LLC | $90.93 |
| Sk Life Science, Inc. | $59.37 |
| Alkermes, Inc. | $45.78 |
| Resmed Corp | $20.18 |
| Axsome Therapeutics, Inc. | $18.96 |
| Food and Beverage | $1,482 |
|---|---|
| Education | $69.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Aug 21, 2025 | Education XYWAV · NEUROLOGY · in-kind | $69.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $238,818 in research payments for these studies, mostly to the institutions running them.
- A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Y…
Jazz Pharmaceuticals Inc. - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Alkermes, Inc. · Completed · NCT06555783 - A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. · Recruiting · NCT06767683 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Alkermes, Inc. · Completed · NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.